Fatal adenoviral hepatitis after rituximab therapy

Archives of Pathology and Laboratory Medicine

Volumn 130, Issue 10, 2006, Pages 1557-1560

  Iyer, Anita ^a   Mathur, Radhika ^b   Deepak, Banglore V ^b   Sinard, John ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIDGEPORT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; GENTAMICIN; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ADENOVIRUS; ADULT; ANASARCA; ANEMIA; ARTICLE; AUTOPSY; BONE MARROW BIOPSY; CASE REPORT; CELL ULTRASTRUCTURE; CLINICAL FEATURE; COUGHING; CYTOARCHITECTURE; DIARRHEA; DRUG FATALITY; DRUG TREATMENT FAILURE; FATIGUE; FEVER; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTHERMIA; LYMPHOCYTIC INFILTRATION; MALE; MULTIPLE ORGAN FAILURE; NEUTROPENIA; OLIGURIA; PANCYTOPENIA; PNEUMONIA; SYMPTOM; VIRUS HEPATITIS; VIRUS INFECTION; WALDENSTROEM MACROGLOBULINEMIA;

ADENOVIRIDAE; ADENOVIRUS INFECTIONS, HUMAN; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FATAL OUTCOME; HEPATITIS, VIRAL, HUMAN; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOLOGIC TECHNIQUES; LIVER; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; STAINING AND LABELING; VIRUS ACTIVATION; WALDENSTROM MACROGLOBULINEMIA;

EID: 33749454405     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
2. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
3. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359-7368.
4. Rituxan: Product Profile and Guide to Clinical Use. South San Francisco, Calif: Genentech Bio-Oncology and IDEC Pharmaceuticals Corporation; 1998.
5. Haura EB, Winden PA, Proia AD, Trotter JF. Infections in oncology: fulminant hepatic failure due to disseminated adenovirus infection in a patient with chronic lymphocytic leukemia. Cancer Control. 2002;9:248-253.
6. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a posttransplantation lymphoproliferative disorder. N Engl J Med. 2001;345:1000.
7. Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica. 2000;85:894-895.
8. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001;344:68-69.
9. Westhoff TH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood. 2003;102:1930.
10. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood. 2000;96:1184-1186.
11. Huang C, Slater B, Rudd R, et al. First isolation of West Nile virus from a patient with encephalitis in the United States. Emerg Infect Dis. 2002;8:1367-1371.
12. Picardi M, Pane F, Quintarelli C, et al. Hepatitis B reactivation after fludarabine-based regimens for indolent nonHodgkins lymphomas: high prevalence of acquired viral genomic mutations. Haematologica. 2003;88:1296-1303.
13. Foran JM, Rahatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric CD20 monoclonal antibody) for patients with newly diagnosed mantle cell lymphoma and previously treated mantle cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317-324.
14. Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high dose chemotherapy with autologous stem cell rescue and peritransplantation rituximab. Blood. 2002;99:1486-1488.
15. + T cells according to IFN-gamma secretion for adjuvant immunotherapy. Exp Hematol. 2004;32:282-289.